Carvedilol Does Not Worsen Gout
Carvedilol is not known to exacerbate gout and is not listed among beta-blockers that increase uric acid levels or precipitate gout flares. In fact, when managing hypertension in patients with gout, carvedilol may be a reasonable choice among beta-blockers.
Key Evidence
Beta-Blockers and Gout Risk
The evidence specifically implicates metoprolol (a selective beta-blocker) as problematic for gout patients. In the AASK trial, metoprolol increased serum uric acid by 0.3-0.4 mg/dL at 12 months and significantly increased the odds of gout-related medication use (OR: 1.62) compared to ramipril 1. This effect was not observed with calcium channel blockers or ACE inhibitors.
Guideline Recommendations for Antihypertensives in Gout
The 2016 EULAR guidelines explicitly address antihypertensive selection in gout patients: "When gout occurs in a patient receiving loop or thiazide diuretics, substitute the diuretic if possible; for hypertension consider losartan or calcium channel blockers" 2. Notably, carvedilol is not mentioned as a drug to avoid, unlike diuretics which are clearly implicated in hyperuricemia.
FDA Label Information
The FDA label for carvedilol (Coreg) lists multiple adverse events but gout appears only once in the entire prescribing information - reported at a frequency of >1% to ≤3% in the CAPRICORN trial (post-MI patients), with the same low frequency as placebo 3. This suggests no causal relationship. The label does not list hyperuricemia or gout as a known adverse effect 3.
Clinical Context
Why This Matters
- Diuretics and selective beta-blockers (like metoprolol) are the antihypertensive classes with established links to hyperuricemia
- Carvedilol is a non-selective beta-blocker with alpha-blocking properties, which may explain its different metabolic profile compared to selective beta-blockers
- The cardiovascular benefits of carvedilol in heart failure and post-MI patients should not be withheld due to unfounded gout concerns
Common Pitfall to Avoid
Do not assume all beta-blockers behave identically regarding uric acid metabolism. The evidence suggests metoprolol specifically increases uric acid, while carvedilol lacks this association. If a patient with gout requires beta-blocker therapy (for heart failure, post-MI, or hypertension), carvedilol appears safer than metoprolol from a gout perspective.
Preferred Antihypertensives in Gout
When selecting antihypertensives for patients with established gout: